A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Active:	No
Cancer Type:	Kidney Cancer Unknown Primary	NCT ID:	NCT04736706
Trial Phases:	Phase III	Protocol IDs:	6482-012 (primary) MK-6482-012 NCI-2021-05629 2020-002216-52
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT04736706

Summary

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus
belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus
pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear
cell renal cell carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior
to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and
overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab
plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS,
in advanced ccRCC participants.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.